Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
Alexander Thomas Cohen(King's College Hospital), Victor F. Tapson(Cedars-Sinai Medical Center), Alex C. Spyropoulos(Northwell Health), Harry R. Büller(Center for Vascular Biology Research), Lloyd Haskell(Johnson & Johnson (United States)), Geno J. Merli(Thomas Jefferson University), Alexandre Mebazaa(Délégation Paris 5), Dayi Hu(Peking University People's Hospital), Sebastian Schellong(Krankenhaus Dresden-Friedrichstadt), Russell D. Hull(Foothills Medical Centre), Theodore E. Spiro(Bayer (United States))
Cited by 120
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
|European Heart Journal|2014|3.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k